Immunitybio Inc (IBRX) Stock Price, Quote & News

Company Profile

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 696 5235

Website: immunitybio.com

Address:

3530 John Hopkins Court, San Diego, United States

Astrid00 Apr. 24 at 3:52 PM

$IBRX

0 · Reply

Buy_SoFi Apr. 24 at 3:48 PM

$IBRX scums doing their very best to take it down to opex max pain

0 · Reply

Zezo88 Apr. 24 at 3:48 PM

$IBRX

0 · Reply

YeboGogo Apr. 24 at 3:46 PM

$IBRX I love this stock 😍🌞

0 · Reply

Iwillbuy Apr. 24 at 3:46 PM

$IBRX I took advantage of that dip to add more… $7.66 added

0 · Reply

jut1 Apr. 24 at 3:43 PM

$IBRX Lets Not Forget... Saudi Arabia Market Entry: On April 21, 2026, the company announced that ANKTIVA is now commercially available in Saudi Arabia for bladder and lung cancer patients, achieving market entry just two months after its regional partnership was announced. Strong Q1 2026 Preliminary Results: Preliminary figures show net product revenue of $44.2 million for Q1 2026, a massive 168% increase year-over-year. Speculation of Japan Deal: Retail traders have recently focused on founder Patrick Soon-Shiong's "quiet" trip to Japan, fueling rumors of a potential major partnership or distribution deal in that market. Financial Strengthening: The company recently secured $100 million in financing, including $75 million in non-dilutive funding, to support global commercialization and its immunotherapy pipeline.

0 · Reply

Nfty Apr. 24 at 3:42 PM

$IBRX heat shock proteins

0 · Reply

Astrid00 Apr. 24 at 3:42 PM

$IBRX

0 · Reply

Nfty Apr. 24 at 3:42 PM

$IBRX study hsp

0 · Reply

tcinptown82 Apr. 24 at 3:40 PM

$IBRX do you hear what i hear??????? yesssss its $6.85 Christmas music is fun too!

0 · Reply

IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt

Apr 22, 2026, 9:00 PM EDT - 1 day ago

IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Apr 21, 2026, 11:21 AM EDT - 3 days ago

IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline

Apr 21, 2026, 9:44 AM EDT - 3 days ago

ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia

Apr 21, 2026, 7:30 AM EDT - 3 days ago

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

Apr 20, 2026, 4:29 PM EDT - 3 days ago

IBRX Stockholders Have Rights – If You Lost Money Investing in ImmunityBio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Apr 20, 2026, 1:33 PM EDT - 3 days ago

ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.

Apr 16, 2026, 9:00 AM EDT - 8 days ago

IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt

Apr 15, 2026, 8:00 PM EDT - 8 days ago

REMINDER: ImmunityBio, Inc. Investors With Significant Losses Must Act By May 26, 2026

Apr 15, 2026, 9:36 AM EDT - 9 days ago

ImmunityBio, Inc. (IBRX) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Apr 9, 2026, 2:11 PM EDT - 14 days ago

Why Is ImmunityBio Stock Rallying Thursday?

Apr 9, 2026, 7:30 AM EDT - 15 days ago

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

Apr 8, 2026, 6:00 PM EDT - 15 days ago

IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role

Apr 6, 2026, 7:30 AM EDT - 18 days ago

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

Apr 1, 2026, 4:07 PM EDT - 22 days ago

ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Mar 31, 2026, 7:30 AM EDT - 24 days ago

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

Mar 27, 2026, 12:17 PM EDT - 27 days ago

$IBRX Lawsuit: ImmunityBio, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

Mar 26, 2026, 10:04 AM EDT - 4 weeks ago

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

Mar 26, 2026, 7:30 AM EDT - 4 weeks ago

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

Mar 24, 2026, 3:25 PM EDT - 4 weeks ago

ImmunityBio stock price crash: buy the dip or sell the rip?

Mar 24, 2026, 12:56 PM EDT - 4 weeks ago

ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 11:04 AM EDT - 4 weeks ago

ImmunityBio Crashes On FDA Warning Over Anktiva Claims

Mar 24, 2026, 10:53 AM EDT - 4 weeks ago

ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad

Mar 20, 2026, 1:08 PM EDT - 4 weeks ago

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

Mar 17, 2026, 1:54 PM EDT - 5 weeks ago

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use

Mar 17, 2026, 7:30 AM EDT - 5 weeks ago

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

Mar 13, 2026, 10:44 AM EDT - 6 weeks ago

Why Is ImmunityBio Stock Soaring On Friday?

Mar 13, 2026, 7:30 AM EDT - 6 weeks ago

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

Mar 9, 2026, 11:03 AM EDT - 6 weeks ago

ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug

Mar 9, 2026, 7:30 AM EDT - 6 weeks ago

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

Feb 27, 2026, 7:30 AM EST - 2 months ago

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

Feb 26, 2026, 8:57 AM EST - 2 months ago

ImmunityBio Investors Rally Behind Cancer Trial Milestone

Feb 26, 2026, 7:30 AM EST - 2 months ago

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feb 25, 2026, 1:02 PM EST - 2 months ago

ImmunityBio Supersedes Expectations With Fivefold Revenue Increase

Feb 25, 2026, 9:09 AM EST - 2 months ago

ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate

Feb 23, 2026, 4:15 PM EST - 2 months ago

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit

Feb 23, 2026, 12:34 PM EST - 2 months ago

ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth

Feb 23, 2026, 7:00 AM EST - 2 months ago

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

Feb 20, 2026, 8:30 AM EST - 2 months ago

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

Feb 19, 2026, 11:37 AM EST - 2 months ago

ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average

Feb 19, 2026, 9:00 AM EST - 2 months ago

ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch

Feb 18, 2026, 12:02 PM EST - 2 months ago

What's Behind The Jump In ImmunityBio Stock?

Feb 18, 2026, 9:00 AM EST - 2 months ago

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

Astrid00 Apr. 24 at 3:52 PM

$IBRX

0 · Reply

Buy_SoFi Apr. 24 at 3:48 PM

$IBRX scums doing their very best to take it down to opex max pain

0 · Reply

Zezo88 Apr. 24 at 3:48 PM

$IBRX

0 · Reply

YeboGogo Apr. 24 at 3:46 PM

$IBRX I love this stock 😍🌞

0 · Reply

Iwillbuy Apr. 24 at 3:46 PM

$IBRX I took advantage of that dip to add more… $7.66 added

0 · Reply

jut1 Apr. 24 at 3:43 PM

0 · Reply

Nfty Apr. 24 at 3:42 PM

$IBRX heat shock proteins

0 · Reply

Astrid00 Apr. 24 at 3:42 PM

$IBRX

0 · Reply

Nfty Apr. 24 at 3:42 PM

$IBRX study hsp

0 · Reply

tcinptown82 Apr. 24 at 3:40 PM

$IBRX do you hear what i hear??????? yesssss its $6.85 Christmas music is fun too!

0 · Reply

AztecPyramid Apr. 24 at 3:39 PM

$IBRX I can't carry any more shares than what I'm holding but I added 6k shares to help contain the short pressure. I know it doesn help much but that's ok. I will sell the 6k back at $8.X and hodl the rest as I've been doing. GL!

1 · Reply

MMM3_432 Apr. 24 at 3:38 PM

$IBRX : I don't understand the call buyers; you know they are trying to plunder you, and yet calls keep being bought. Apparently, these call option buyers want to go under. Soon, when the stock price really starts to rise, these option buyers will have no cash left....

0 · Reply